PRELUDE THERAPEUTICS INC (PRLD) Stock Price, Quote, News and Overview
NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD
PRLD Quote, Performance and Key Statistics
0.8862
-0.01 (-1.54%)
The current stock price of PRLD is 0.8862 USD. In the past month the price decreased by -1.63%. In the past year, price decreased by -78.33%.
PRLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About PRLD
Company Profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Company Info
PRELUDE THERAPEUTICS INC
175 Innovation Boulevard
Wilmington DELAWARE 19803 US
CEO: Krishna Vaddi
Employees: 131
Phone: 13024671280
PRELUDE THERAPEUTICS INC / PRLD FAQ
What is the stock price of PRELUDE THERAPEUTICS INC today?
The current stock price of PRLD is 0.8862 USD. The price decreased by -1.54% in the last trading session.
What is the ticker symbol for PRELUDE THERAPEUTICS INC stock?
The exchange symbol of PRELUDE THERAPEUTICS INC is PRLD and it is listed on the Nasdaq exchange.
On which exchange is PRLD stock listed?
PRLD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRELUDE THERAPEUTICS INC stock?
9 analysts have analysed PRLD and the average price target is 5.1 USD. This implies a price increase of 475.49% is expected in the next year compared to the current price of 0.8862. Check the PRELUDE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRELUDE THERAPEUTICS INC worth?
PRELUDE THERAPEUTICS INC (PRLD) has a market capitalization of 50.03M USD. This makes PRLD a Micro Cap stock.
How many employees does PRELUDE THERAPEUTICS INC have?
PRELUDE THERAPEUTICS INC (PRLD) currently has 131 employees.
What are the support and resistance levels for PRELUDE THERAPEUTICS INC (PRLD) stock?
PRELUDE THERAPEUTICS INC (PRLD) has a support level at 0.87 and a resistance level at 0.91. Check the full technical report for a detailed analysis of PRLD support and resistance levels.
Is PRELUDE THERAPEUTICS INC (PRLD) expected to grow?
The Revenue of PRELUDE THERAPEUTICS INC (PRLD) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PRLD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRELUDE THERAPEUTICS INC (PRLD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRLD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRLD, evaluating the profitability, health, valuation and growth aspects
- PRELUDE THERAPEUTICS INC (PRLD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRELUDE THERAPEUTICS INC (PRLD) Sales and EPS estimates to see what analysts future expectations are.
- PRELUDE THERAPEUTICS INC (PRLD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRELUDE THERAPEUTICS INC (PRLD) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRELUDE THERAPEUTICS INC (PRLD) Stock Chart to make your own analysis
- PRELUDE THERAPEUTICS INC (PRLD) Latest news and press-releases to stay up to date.
Does PRELUDE THERAPEUTICS INC (PRLD) stock pay dividends?
PRLD does not pay a dividend.
When does PRELUDE THERAPEUTICS INC (PRLD) report earnings?
PRELUDE THERAPEUTICS INC (PRLD) will report earnings on 2025-11-04, before the market open.
What is the Price/Earnings (PE) ratio of PRELUDE THERAPEUTICS INC (PRLD)?
PRELUDE THERAPEUTICS INC (PRLD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.69).
What is the Short Interest ratio of PRELUDE THERAPEUTICS INC (PRLD) stock?
The outstanding short interest for PRELUDE THERAPEUTICS INC (PRLD) is 4.44% of its float. Check the ownership tab for more information on the PRLD short interest.
PRLD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PRLD. When comparing the yearly performance of all stocks, PRLD is a bad performer in the overall market: 90.16% of all stocks are doing better.
PRLD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRLD. PRLD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRLD Financial Highlights
Over the last trailing twelve months PRLD reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS increased by 9.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.46% | ||
| ROE | -96.74% | ||
| Debt/Equity | 0 |
PRLD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to PRLD. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -0.25% and a revenue growth -100% for PRLD